LONDON, Aug. 20, 2015 /PRNewswire/ -- Global Molecular Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Molecular Diagnostics 2010-2015 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all molecular diagnostics partnering deals announced since 2010 including financial terms where available including over 300 links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of the report provide an orientation of molecular diagnostics dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in molecular diagnostics deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.
A popular chapter with readers chapter 3 covers the average financial deal terms for deals signed in the molecular diagnostics field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.
Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in molecular diagnostics partnering and dealmaking since 2010.
Chapter 4 covers the leading cancer diagnostics deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active molecular diagnostics deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma companies.
Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the cancer diagnostics partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database.
Chapter 6 brings the report to a conclusion by looking ahead to the future of molecular diagnostics partnering. Newly introduced to provide readers with potential prospects and partnering insights this chapter selects emerging companies to watch in 2015 and details their recent deal making and financial activities. These companies could be potential targets for those who want to invest or partner in the coming months.
In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the molecular diagnostics field preparing them with everything they need to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.
A full appendix is provided at the very end of the report which lists all the cancer diagnostics deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.
Global Molecular Diagnotsics Partnering 2010-2015 provides the reader with the following key benefits:
In-depth understanding of molecular diagnostics deal trends since 2010
Access molecular diagnostics deal headline, upfront, milestone and royalty data
Analysis of the structure of molecular diagnostics agreements with numerous real life case studies
Comprehensive access to over 300 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples
Identify leading molecular diagnostics deals by value since 2010
Identify the most active molecular diagnostics dealmakers since 2010
Insight into the terms included in molecular diagnostics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Download the full report: https://www.reportbuyer.com/product/3158264/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48